Managing chemotherapy induced anemia with darbepoetin alfa and other erythropoiesis stimulating agents: a nurse's perspective

References

• Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40(15):2293–2306.
   PubMed Web of Science ®Google Scholar
• Spano JP, Khayat D. Treatment options for anemia, taking risks into consideration: erythropoiesis-stimulating agents versus transfusions. Oncologist. 2008;13 Suppl 3:27–32.
   Google Scholar
• Kleinman L, Benjamin K, Viswanathan H, et al. The anemia impact measure (AIM): development and content validation of a patient-reported outcome measure of anemia symptoms and symptom impacts in cancer patients receiving chemotherapy. Qual Life Res. 2012;21(7): 1255–1266.
   Web of Science ®Google Scholar
• Curt GA. Impact of fatigue on quality of life in oncology patients. Sem in Hematol. 2000;37(4 Suppl 6):14–17.
   PubMed Web of Science ®Google Scholar
• Stone P Richardson A, Ream E, Smith AG, Kerr DJ, Kearney N. Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann Oncol. 2000;11(8):971–975.
   PubMed Web of Science ®Google Scholar
• Loge JH, Abrahamsen AF, Ekeberg, Kaasa S. Fatigue and psychiatric morbidity among Hodgkin’s disease survivors. J Pain Symptom Manage. 2000;19(2):91–99.
   Web of Science ®Google Scholar
• Wang XS, Giralt SA, Mendoza TR, et al. Clinical factors associated with cancer-related fatigue in patients being treated for leukemia and non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20(5):1319–1328.
   Web of Science ®Google Scholar
• Bloom JR, Gorsky RD, Fobair P, et al. Physical performance at work and at leisure. Validation of a measure of biological energy in survivors of Hodgkin’s disease. J Psychosoc Oncol. 1990;8(1):49–63.
   Google Scholar
• Morrow GR, Andrews PL, Hickok JT, Roscoe JA, Matteson S. Fatigue associated with cancer and its treatment. Support Care Cancer. 2002;10(5):389–398.
   Web of Science ®Google Scholar
• Hjermstad MJ, Fossa SD, Oldervoll L, Holte H, Jacobsen AB, Loge JH. Fatigue in long-term Hodgkin’s Disease survivors: a follow-up study. J Clin Oncol. 2005;23(27):6587–6595.
   PubMed Web of Science ®Google Scholar
• Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999;91(19):1616–1634.
   PubMed Web of Science ®Google Scholar
• Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood. 2008;111(1):25–41.
   PubMed Web of Science ®Google Scholar
• Seidenfeld J, Piper M, Flamm C, et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and metaanalysis of controlled clinical trials. J Natl Cancer Inst. 2001;93(16): 1204–1214.
   Google Scholar
• Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol. 2003;31(4):290–299.
   PubMed Web of Science ®Google Scholar
• Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer. 2001; 84 Suppl 1:3–10.
   Google Scholar
• Vansteenkiste J, Pirker R, Massuti B, et al; Aranesp 980297 Study Group. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 2002;94(16):1211–1220.
   PubMed Web of Science ®Google Scholar
• Hedenus M, Hansen S, Taylor K, et al; Darbepoetin alfa 990114 Study Group. Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol. 2002;119(1):79–86.
   Web of Science ®Google Scholar
• Hedenus M, Adriansson M, San Miguel J, et al; Darbepoetin Alfa 20000161 Study Group. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, doubleblind, placebo-controlled study. Br J Haematol. 2003;122(3):394–403.
   PubMed Web of Science ®Google Scholar
• Glaspy JA, Jadeja JS, Justice G, et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer. 2002;87(3):268–276.
   PubMed Web of Science ®Google Scholar
• Glaspy JA, Tchekmedyian NS. Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy. Oncology (Williston Park). 2002;16(10 Suppl 11):23–29.
   Web of Science ®Google Scholar
• Glaspy J, Vadhan-Raj S, Patel R, et al; 20030125 Study Group Trial. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. J Clin Oncol. 2006;24(15):2290–2297.
   Web of Science ®Google Scholar
• Schwartzberg LS, Yee LK, Senecal FM, et al. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist. 2004;9(6):696–707.
   Web of Science ®Google Scholar
• Canon JL, Vansteenkiste J, Bodoky G, et al. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst. 2006;98(4): 273–284.
   PubMed Web of Science ®Google Scholar
• Kotasek D, Canon JL, Mateos MV, Hedenus M, Rossi G, Taylor K. A randomized, controlled trial comparing darbepoetin alfa correction/maintenance dosing with weekly dosing for treating chemotherapy-induced anemia. Curr Med Res Opin. 2007;23(6):1387–1401.
   PubMed Web of Science ®Google Scholar
• Glaspy J, Henry D, Patel R, et al; Darbepoetin Alfa 20010162 Study Group. Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer. 2005;41(8):1140–1149.
   PubMed Web of Science ®Google Scholar
• de Jong FA, Viala-Danten M, van Herwaarden RH, et al. Psychometric validation of a patient questionnaire evaluating satisfaction with a darbepoetin alpha pre-filled device for self-injection (Aranesp®SureClickTMdevice), and a home-service (2care®service) in chemotherapy-induced anaemic cancer patients. Abstract presented at: ISPOR 15th Annual International Meeting; May 15–19, 2010; Atlanta, GA.
   Google Scholar
• Vadhan-Raj S, Mirtsching B, Charu V, et al. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks. J Support Oncol. 2003;1(2):131–138.
   PubMedGoogle Scholar
• Esquerdo G, Llorca C, Cervera JM, Orts D, Juárez A, Carrato A. Effectiveness of darbepoetin alfa in a cohort of oncology patients with chemotherapy-induced anaemia. Relationship between variation in three fatigue-specific quality of life questionnaire scores and change in haemoglobin level. Clin Transl Oncol. 2011;13(5):341–347.
   Web of Science ®Google Scholar
• Vansteenkiste J, Tomita D, Rossi G, Pirker R. Darbepoetin alfa in lung cancer patients on chemotherapy: a retrospective comparison of outcomes in patients with mild versus moderate-to-severe anaemia at baseline. Support Care Cancer. 2004;12(4):253–262.
   PubMed Web of Science ®Google Scholar
• Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation. 2003;107(23 Suppl 1):I17–121.
   PubMed Web of Science ®Google Scholar
• Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299(8):914–924.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Rajkumar SV, Dimopoulos MA, et al; International Myeloma Working Group. Prevention of thalidomide- and lenalidomide- associated thrombosis in myeloma. Leukemia. 2008;22(2):414–423.
   PubMed Web of Science ®Google Scholar
• Snowden JA, Ahmedzai SH, Ashcroft J, et al; Haemato-oncology Task Force of British Committee for Standards in Haematology and UK Myeloma Forum. Guidelines for supportive care in multiple myeloma 2011. Br J Haematol. 2011;154(1):76–103.
   PubMed Web of Science ®Google Scholar
• Henke M, Laszig R, Rübe C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, doubleblind, placebo-controlled trial. Lancet. 2003;362(9392):1255–1260.
   PubMed Web of Science ®Google Scholar
• Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 2005;23(25):5960–5972.
   PubMed Web of Science ®Google Scholar
• Overgaard J, Hoff C, Sand Hansen H, et al. Randomized study of the importance of Novel Erythropoiesis Stimulating Protein (Aranesp) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC) – the Danish Head and Neck Cancer Group DAHANCA 10 randomized trial. Eur J Cancer. 2007;5:7. Abstract.
   Web of Science ®Google Scholar
• Smith RE, Aapro MS, Ludwig H, et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol. 2008;26(7): 1040–1050.
   PubMed Web of Science ®Google Scholar
• Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol. 2007;25(9):1027–1032.
   PubMed Web of Science ®Google Scholar
• Untch M, Fasching PA, Konecny GE, et al; Arbeitsgemeinschaft Gynäkologische Onkologie PREPARE investigators. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer – results at the time of surgery. Ann Oncol. 2011;22(9):1988–1998.
   Web of Science ®Google Scholar
• Thomas G, Ali S, Hoebers FJ, et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol. 2008;108(2):317–325.
   PubMed Web of Science ®Google Scholar
• Untch M, von Minckwitz G, Konecny GE, et al; Arbeitsgemeinschaft Gynäkologische Onkologie PREPARE investigators. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer – outcome on prognosis. Ann Oncol. 2011;22(9):1999–2006.
   PubMed Web of Science ®Google Scholar
• Hedenus M, Vansteenkiste J, Kotasek D, Austin M, Amado RG. Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, doubleblind, placebo-controlled trials. J Clin Oncol. 2005;23(28):6941–6948.
   Web of Science ®Google Scholar
• Nitz U, Gluz O, Oberhoff C, et al. Adjuvant chemotherapy with or without darbepoetin alpha in node-positive breast cancer: survival and quality of life analysis from the prospective randomized WSG ARA Plus trial. Abstract presented at: San Antonio Breast Cancer Symposium (SABCS); December 6–10, 2011; San Antonio, TX.
   Google Scholar
• Delarue R, Haioun C, Coiffier B, et al. Survival effect of darbepoetin alfa in patients with diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: The LNH03–6B study. J Clin Oncol. 2011;29(Suppl):Abstract 9048.
   Google Scholar
• Pirker R, Ramlau RA, Schuette W, et al. Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. J Clin Oncol. 2008;26(14): 2342–2349.
   Web of Science ®Google Scholar
• Aapro MS, Link H. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist. 2008;13 Suppl 3:33–36.
   Google Scholar
• Bokemeyer C, Aapro MS, Courdi A, et al; European Organisation for Research and Treatment of Cancer (EORTC) Taskforce for the Elderly. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer. 2007;43(2):258–270.
   PubMed Web of Science ®Google Scholar
• Schrijvers D, De Samblanx H, Roila F; ESMO Guidelines Working Group. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann Oncol. 2010;21 Suppl 5:v244–v247.
   Google Scholar
• Rizzo JD, Brouwers M, Hurley P, et al; American Society of Clinical Oncology; American Society of Hematology. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol. 2010;28(33):4996–5010.
   PubMed Web of Science ®Google Scholar
• Tonelli M, Hemmelgarn B, Reiman T, et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a metaanalysis. CMAJ. 2009;180(11):E62–E71.
   PubMed Web of Science ®Google Scholar
• Bohlius J, Schmidlin K, Brillant C, et al. Erythropoietin or Darbepoetin for patients with cancer – meta-analysis based on individual patient data [review]. Cochrane Database Syst Rev. 2009;3:CD007303.
   Google Scholar
• Ludwig H, Crawford J, Osterborg A, et al. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol. 2009;27(17):2838–2847.
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Glaspy J, Henry D, et al. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. Lung Cancer. 2012;76(3): 478–485.
   PubMed Web of Science ®Google Scholar
• Hedenus M, Osterborg A, Tomita D, Bohac C, Coiffier B. Effects of erythropoiesis-stimulating agents on survival and other outcomes in patients with lymphoproliferative malignancies: a study-level metaanalysis. Leuk Lymphoma. 2012;53(11):2151–2158.
   PubMed Web of Science ®Google Scholar
• Glaspy J, Crawford J, Vansteenkiste J, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer. 2010;102(2):301–315.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence (NICE). Epoetin alfa, epoetin beta and darbepoetin alfa for cancer treatment-induced anaemia (technology appraisal guidance 142). London: National Institute for Health and Clinical Excellence; 2008.
   Google Scholar
• Bittner N, Kipkova A, Móciková H, Woj ciechowska-Lampka E, Balazs M, Ocvirk J. Current management of chemotherapy-induced anemia with darbepoetin alfa – the apriori study. J Clin Oncol. 2011;29(Suppl): Abstract e19723.
   Google Scholar
• Van Belle S, Karanikiotis C, Labourey JL, Galid A, Wheeler T, Pujol B. Current practice of darbepoetin alfa in the management of haemoglobin levels in cancer patients undergoing chemotherapy – data from the CHOICE study. Curr Med Res Opin. 2011;27(5):987–994.
   PubMed Web of Science ®Google Scholar
• Aerts JG, Swieboda-Sadlej A, Karanikiotis C, et al. Use of darbepoetin alfa in European clinical practice for the management of chemotherapy-induced anaemia in four tumour types: final data from the CHOICE study. Curr Med Res Opin. 2012;28(7):1089–1099.
   PubMed Web of Science ®Google Scholar
• Bustos A, Álvarez R, Aramburo PM, et al; RADAR Study Group. Evaluation of clinical use and effectiveness of darbepoetin alfa in cancer patients with chemotherapy-induced anemia. Curr Med Res Opin. 2012;28(1):57–67.
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Hedenus M, Gascon P, et al. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level <10 g/dL versus > or =10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial. BMC Cancer. 2009;9:311.
   PubMed Web of Science ®Google Scholar
• Van Belle S, Swieboda-Sadlej A, Karanikiotis C, et al. A final analysis from the CHOICE study examining darbepoetin alfa use for chemotherapy-induced anaemia in current European clinical practice. Curr Med Res Opin. 2012;28(7):1079–1087.
   PubMed Web of Science ®Google Scholar
• Pirker R, Collins H, Legg JC, Vansteenkiste J. Rate of hemoglobin (Hb) decline from <10 g/dL to <9 g/dL in placebo-treated patients (pts) receiving chemotherapy: A pooled analysis of data from 6 randomized darbepoetin alfa trials. J Clin Oncol. 2011;29(Suppl):Abstract e19637.
   Google Scholar
• Pirolli M, Collins H, Hulnick S, Quigley J. Rate of hemoglobin (Hb) decline from <10 g/dL to <9 g/dL by electronic medical-record (EMR) evaluation in community oncology patients (pts) receiving chemotherapy in the absence of erythropoiesis-stimulating agents (ESAs). J Clin Oncol. 2011;29(Suppl):Abstract e19625.
   Google Scholar
• Deger M, Eisterer W, Kutikova L, Salek S. Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe. Support Care Cancer. 2013;21(2):485–493.
   PubMed Web of Science ®Google Scholar
• Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010;363(4):301–304.
   PubMed Web of Science ®Google Scholar
• Harrison LB, Shasha D, White C, Ramdeen B. Radiotherapy-associated anemia: the scope of the problem. Oncologist. 2000;5 Suppl 2:1–7.
   Google Scholar
• Amgen. Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia. Available from http://clinicaltrials.gov/show/NCT01444456. NLM identifier: NCT01444456. Accessed October 7, 2013.
   Google Scholar
• Balducci L. Anemia, cancer, and aging. Cancer Control. 2003;10(6): 478–486.
   Google Scholar
• Ludwig H, Wedding U, Van Belle S. Anaemia in elderly patients with cancer: focus on chemotherapy-induced anaemia. J Geriatr Oncol. 2012;3(3):256–264.
   Web of Science ®Google Scholar
• Amgen. Darbepoetin Alfa in Anemic Low or Intermediate-1 Risk MDS Subjects. Available from http://clinicaltrials.gov/show/NCT01362140. NLM identifier: NCT01362140. Accessed October 7, 2013.
   Google Scholar
• Amgen. Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy. Available from http://clinicaltrials.gov/show/NCT00858364. NLM identifier: NCT00858364. Accessed October 7, 2013.
   Google Scholar
• McLaughlin TM, Wittstein ER, White TH, Czaplinski CA, Gerard SO. Moving to wellness: a pilot study examining a nurse-driven exercise program in acutely ill patients with cancer. Clin J Oncol Nurs. 2012;16(3):E105–E110.
   Google Scholar
• Spector D, Battaglini C, Alsobrooks A, Owen J, Groff D. Do breast cancer survivors increase their physical activity and enhance their health-related quality of life after attending community-based wellness workshops? J Cancer Educ. 2012;27(2):353–361.
   Google Scholar
• Stricker CT, Drake D, Hoyer KA, Mock V Evidence-based practice for fatigue management in adults with cancer: exercise as an intervention. Oncol Nurs Forum. 2004;31(5):963–976.
   PubMed Web of Science ®Google Scholar